141 results about "Genus Brucella" patented technology

The invention provides a kit for rapidly detecting brucella in a blood sample, relating to the technical field of fingerprint spectrum detection of proteins. According to the kit, based on the mass-spectrometric technique, a specific polypeptide mass-spectrometric model aiming at brucella detection in the blood is constructed, and a kit for carrying out the brucella detection by utilizing the mass-spectrometric technique is constructed. According to the kit provided by the invention, the brucella in the blood sample can be authenticated by utilizing a specific fingerprint spectrum, the accuracy is high, and the repeatability is good; the detection on 96 samples can be finished within 2 hours and can be finished at least 5 days in advance compared with the detection time in the conventional detection method; the detection cost is low, and the result is reliable, so that the kit has a good application prospect.

The invention relates to a primer, probe and reagent kit for identifying Brucella S2 vaccine strains in aerocolloid. The forward primer sequence of Brucella-RPA-LFD is shown as SEQIDNo.1, the backward primer sequence of Brucella-RPA-LFD is shown as SEQIDNo.2, and the probe sequence of Brucella-RPA-LFD is shown as SEQIDNo.3; the forward primer sequence of S2-RPA-LFD is shown as SEQIDNo.4, the backward primer sequence of S2-RPA-LFD is shown as SEQIDNo.5, and the probe sequence of S2-RPA-LFD is shown as SEQIDNo.6. The combination of the RPA-LFD primer and the probe, or the reagent kit, for identifying and diagnosing the Brucella S2 vaccine strains, provided by the invention are high in sensitivity and specificity, and can at least detect 2.5*100 cfu of Brucella or the Brucella S2 vaccine strains.

The invention relates to a low virulent strain of Brucella and a vaccine thereof. According to a vaccine strain, a coarse low virulent strain RA343 of Brucella abortus is screened through a domestication and selection technology combining antibiotics and A-factor serum. The coarse low virulent strain is remarkably improved in safety and still remains a good immune effect on the Brucella is still maintained. A Brucella vaccine prepared by using the low virulent strain is to change the current situation that Brucella vaccine-immunized animals and wild strain-infected animals are hard to differentiate, and the safety of existing vaccine is effectively improved.

The invention discloses an animal brucella antibody gold mark rapid detection kit and belongs to the field of animal disease detection. The kit consists of two parts namely a card box and a test strip, wherein the card box comprises a box cover (4) and a box bottom (7), and the detection test strip is placed in the card box; a sampling hole (1) and an inspection window (2) are formed in the front side of the card box, and a sampling hole label (5), a result judging specification (6) and an information recording column (3) are printed on the front side of the box cover. According to the invention, the colloidal gold immunochromatography technology is adopted, a brucella BP26, OMP25 or OMP31 pathogen in engineering expression is used as the detection pathogen, a mouse anti-bovine IgG monoclonal antibody, a mouse anti-goat IgG monoclonal antibody or a mouse anti-swine IgG monoclonal antibody is used the capture antibody, and an indirect process detection kit is made. The animal brucella antibody gold mark rapid detection kit can be used for detecting the brucella antibody in the serum, the plasma or the whole blood of cattle, goats or swines and has the advantages of simple detection method, accurate and rapid result display and no requirement of special instruments or equipment.

The invention aims to provide a brucellosis indirect enzyme-linked immunosorbent assay antibody detection kit which has moderate cost and short reaction time and is closely combined with the requirements of actual detection and general survey operations in China. The brucellosis indirect enzyme-linked immunosorbent assay antibody detection kit is assembled by using a purified lipopolysaccharide mixture of smooth type brucella and rough type brucella as antigen coated wells, using S1119.3 immune and healthy cattle to prepare positive control serum and standard weak positive serum, using healthy and non-immune cattle serum as negative control serum, using protein AG which is labeled by enzyme and is a receptor in combination with mammal Fc segment as enzyme labeling combo, and together taking serum diluent, a cleaning solution, a substrate solution A, a substrate solution B, H2O2 and a stopping solution as coordination. The invention establishes a rapid, sensitive, special and accurate method suitable for brucellosis diagnosis and epidemiological survey, has objective result judgment, simple and convenient operation, and is suitable for both large-scale screening tests and final confirmed diagnosis of the brucellosis.

The invention relates to a recombined brucella melilitensis, wherein the recombined brucella melilitensis completely deletes the bp26 gene. Safe tests prove that the brucella melilitensis is consistent with a parent vaccine strain. Virulent attack protection tests prove that a mutant strain has immune protection consistent with the parent vaccine strain. The mutant strain has significance for distinguishing vaccine immunity from wild type brucellosis infection from the standpoint of serology and controlling, monitoring and purifying brucellosis disease.

A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.